Abstract 518P
Background
Artificial Intelligence (AI) holds the promise to transform medicine during diagnosis, management and therapy of diseases. The AICCELERATE project will introduce an operational approach to develop AI-enabled digital solutions to improve medical processes by creating a digital twin. In our study, we performed the first pilot application of the AICCELERATE project at Bambino Gesù Children’s Hospital in Rome (OPBG). The aim of our study is to design a supervised machine learning (ML) model to predict time to surgery and time to diagnosis based (outputs) on time from admission to first consultation and imaging (inputs) in newly diagnosed pediatric patients.
Methods
We included pediatric patients with new diagnoses of brain tumors, treated in OPBG from December 2017 to December 2022. We collected from EHR the following data: age and sex, start and end date of the first admission, department of hospitalization, consultations and radiological imaging date, diagnosis, and surgery date.
Results
We included 48 patients with a pediatric brain tumor, with a mean age of 8.6 years. We used a multiple linear regression model, which does not require large datasets such as more complex models. Our analysis showed that delayed consulting and imaging led to a delayed diagnosis, with the consulting presenting a higher importance than the imaging. This result was validated by the model’s estimated regressors coefficients, with the consulting factor being assigned a larger weight β_C=1.81 than the imaging factor β_I=-0.33. Similarly, we observed that delayed consulting and imaging led to a delayed surgery, estimating a higher coefficient for the consulting β_C=0.71 than the one estimated for the imaging β_I=-0.06. While the ML model achieved a reasonable performance in both frameworks, the time to surgery was predicted with a lower MAE 4.45±0.87 compared to the diagnosis MAE of 6.74±0.95.
Conclusions
This preliminary study conducted in a small number of patients, suggests that decreasing time to consultation can shorten time to surgery in children with brain cancer. As the AICCELERATE is ongoing, more accurate models will be developed and will help to better understand how to optimize the journey of children with brain cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
592P - The role of early change in circulating tumor DNA as a potential predictor of response to chemotherapy in patients with metastatic colorectal cancer
Presenter: Jinjia Chang
Session: Poster session 10
594P - The efficacy of anti-EGFR therapy for RAS mutant metastatic colorectal cancer (mCRC) patients with RAS mutation negative in circulating-tumor DNA (ctDNA) after 1st- or 2nd-line chemotherapy
Presenter: Naoki Izawa
Session: Poster session 10
595P - The DUREC trial: Durvalumab plus total neoadjuvant therapy in locally advanced rectal cancer - a multicenter, single-arm, phase II study (GEMCAD-1703)
Presenter: Jaume Capdevila Castillon
Session: Poster session 10
597P - Surgical quality for patients (pts) treated with neoadjuvant chemotherapy vs chemoradiation for locally advanced rectal cancer (LARC): PROSPECT (NCCTG N1048, alliance)
Presenter: Martin Weiser
Session: Poster session 10
598P - Influence of the early stoma closure after low rectal cancer resection on completeness of adjuvant chemotherapy (CoCStom): A randomized, controlled multicentre trial of the AIO (AIO KRK 0113)
Presenter: Flavius Sandra-Petrescu
Session: Poster session 10
599P - R-IMMUNE: A phase Ib/II study to evaluate safety and efficacy of atezolizumab combined with radio-chemotherapy in a preoperative setting for patients with locally advanced rectal cancer (LARC)
Presenter: Javier Carrasco
Session: Poster session 10